ARTICLE

FindCenter AddIcon

Microdose Research: Without Approvals, Control Groups, Double-Blinds, Staff or Funding

By James Fadiman — 2017

There is an abundance of good news. After forty plus years of research being denied, what Charles Grob kindly called, “a lull,” psychedelic science is back.

Read on psychedelicpress.co.uk

FindCenter Post-Image

An Introduction to MDMA

Once considered the quintessential party drug, MDMA (also known as “ecstasy,” “X,” or “molly”) is now experiencing a surge of interest in a completely different area: psychedelic-assisted psychotherapy.

Article
FindCenter
2022
FindCenter AddIcon
FindCenter Post-Image

An Introduction to LSD

LSD, or lysergic acid diethylamide, is a synthetic drug with potent psychedelic properties. Commonly known as acid, it was originally derived from compounds found in ergot, a fungus that grows on rye.

Article
FindCenter
2022
FindCenter AddIcon
FindCenter Post-Image

A Brief History of Psychedelic Psychiatry

In the 1950s a group of pioneering psychiatrists showed that hallucinogenic drugs had therapeutic potential, but the research was halted as part of the backlash against the hippy counterculture.

Article
Mo Costandi
2014
FindCenter AddIcon
FindCenter Post-Image

Inside The Movement To Decolonize Psychedelic Pharma

As Western medicine brings psychedelics into mainstream use, a growing movement is innovating new business models grounded in reciprocity and inclusion.

Article
Carolyn Gregoire
2020
FindCenter AddIcon
FindCenter Post-Image

Psychedelic Therapy and Racial Trauma: Offering Clients a Deeper Experience of Healing

Like most people of color in the United States, psychotherapist and researcher Monnica Williams has experienced myriad forms of racism. Early in her career, understanding its effects on her mind and body motivated her to help clients address their own racial trauma in therapy.

Article
Chris Lyford
2021
FindCenter AddIcon
FindCenter Post-Image

The Cost of Exclusion in Psychedelic Research

In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants.

Article
Xinyuan Chen, Mackenzie Bullard, Christy Duan, Jamilah R. George, Terence Ching, Stephanie Kilpatrick, Jordan Sloshower, Monnica Williams
2020
FindCenter AddIcon
FindCenter Post-Image

Psychedelic Psychotherapy Is Coming: Who Will Be Included?

A new study finds widespread exclusion of minorities in psychedelic research.

Article
Monnica T. Williams
2018
FindCenter AddIcon
FindCenter Post-Image

How Researchers and Advocates of Color Are Forging Their Own Paths in Psychedelic-Assisted Therapy

We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.

Article
Steph Yin
2020
FindCenter AddIcon
FindCenter Post-Image

Study Finds Ketamine Can Help Patients Manage Depression and PTSD

Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.

Article
Hannah Sabourin
2021
FindCenter AddIcon
FindCenter Post-Image

Who Will Benefit From Psychedelic Medicine?

These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.

Article
Whitney Joiner
2020
FindCenter AddIcon

EXPLORE TOPIC

Microdosing